Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GRN | P28799 | 1/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5008332 | 0.85 | MAPK14 (0.48) | MAPK14KDM4EGRNSORT1MAPT | |
| SCHEMBL5008530 | 0.82 | MAPK14 (0.52) | MAPK14KDM4EGRNSORT1MAPT | |
| SCHEMBL5008343 | 0.81 | MEN1 (0.50) | MAPK14KDM4EGRNSORT1MAPT | |
| SCHEMBL5640986 | 0.74 | MAPK14 (0.49) | MAPK14MAPTMAPK13MAPK12MAPK11 | |
| SCHEMBL5007711 | 0.72 | MAPK14 (0.47) | MAPK14MAPTMAPK13MAPK12MAPK11 | |
| SCHEMBL5010551 | 0.72 | MAPK14 (0.45) | MAPK14KDM4EGRNSORT1MAPT | |
| SCHEMBL3974243 | 0.71 | DHODH (0.50) | MAPK14KDM4EGRNSORT1MAPT | |
| SCHEMBL13752293 | 0.71 | MAPK14 (0.43) | MAPK14KDM4EGRNSORT1MAPT | |
| SCHEMBL5469997 | 0.71 | SMN1; SMN2 (0.47) | KDM4EMAPT | |
| SCHEMBL7332729 | 0.71 | MCL1 (0.43) | MAPK14KDM4EMAPTMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | MAPK14 1938/4885KDM4E 3005/4885GRN 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.